Sign In
glob
Find HeartFlow

PRECISE Trial Rewrites the Patient Pathway

Helping physicians get the right patient, the right care at the right time.

This image is not an accurate representation of the HeartFlow product

The PRECISE Trial

It’s confirmed. The Precision Pathway recognized in the AHA/ACC guidelines — centered around Coronary CTA+FFRCT — is superior to Traditional Testing, which prioritizes functional (stress) testing and Invasive Coronary Angiography (ICA).1

Physician Perspectives on the PRECISE Trial

vid thumb 1

The PRECISE Trial – A conversation with Dr. James Udelson, Tufts Medical Center

vid thumb 2

KOLs Agree! PRECISE supports Chest Pain Guidelines, CCTA+FFRCT Pathway good for patient care, cath lab efficiency

vid thumb 3

PRECISE 1 Year Results Quick Summary with Pam Douglas

A closer look at the PRECISE Trial

Webinar: This panel of leading experts discusses insights from the PRECISE Trial 1-Year data, how the findings relate to the 2021 AHA/ACC Chest Pain Guidelines, and what the data tell us about different strategies for the evaluation and diagnosis of coronary artery disease. Featuring Dr. Pamela S. Douglas, Dr. Maros Ferencik, and Dr. Gregg W. Stone

Watch Now

1-Year Primary Endpoint Results

The Precision Pathway, centered around CCTA+FFRCT, achieved its primary endpoint by significantly reducing the composite of all-cause death, nonfatal MI, or catheterization without obstructive disease relative to Traditional Testing at 1 year.

Key Findings

Precision Pathway compared to Traditional Testing:

65

Global Sites

2,103

Patients

Adjudicated

Core Lab, CEC2
 

Precision Pathway

Risk scoring to defer testing for low-risk patients.3

CCTA with selective FFRCT4 for elevated risk patients.

Traditional Testing

Functional testing (stress nuclear and stress echo) and Invasive Coronary Angiography (ICA).

More accurate non-invasive diagnosis

Fewer unnecessary tests

Reduced long-term risk by increasing preventive therapies5

 
Download the Data Sheet

The PRECISE Trial Design

Patients with non-acute chest pain or the equivalent requiring testing for suspected CAD.

No history of Obstructive CAD or CAD testing < 1 year: N=2103

Randomized into one of two pathways.
Randomization stratified by site, PROMISE Minimal Risk Score (Low Risk vs. Elevated Risk), and intended first test (if randomized to Traditional Testing).

All subsequent care and testing decisions made by site clinician.
Guideline-directed medical management recommended for all.

Primary Endpoint (1 year)
Death, Nonfatal MI, Cath without obstructive CAD

Secondary Endpoints
Death, Nonfatal MI, Unplanned CV Hospitalizations, Radiation, Preventive Medication Use, Cath Yield, Resource Use, Quality of Life

Download the Data Sheet

REFERENCES

  1. Douglas, et al. Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease. JAMA Cardiol. 2023. 
  2. Clinical Events Committee (CEC)
  3. Patient risk was determined using the PROMISE Minimal Risk Score. PROMISE variables include: age, sex, ethnicity, smoking history, diabetes mellitus, dyslipidemia, family history of premature coronary artery disease, hypertension, symptoms related to stress and high-density lipoprotein (HDL) concentration.
  4. For stenoses 30-90%
  5. Joshi, et al. JAMA 2021.
cert logo hitrust.7394f2b.cda83af2e008d8cc68f55103dbde7712

The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.

© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041

173961488 v2

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます！

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？

いいえ
はい